Wadenberg M L, Cortizo L, Ahlenius S
Department of Psychology, University of Stockholm, Sweden.
Pharmacol Biochem Behav. 1994 Mar;47(3):509-13. doi: 10.1016/0091-3057(94)90152-x.
Administration of the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.1 mg kg-1 SC) completely antagonised the catalepsy produced by the dopamine (DA) D2 receptor antagonist raclopride (16 mg kg-1 SC). This effect by 8-OH-DPAT was in turn completely antagonised by treatment with the new 5-HT1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(di-n-propylamino)tetralin [(S)-UH-301] (3.5 mg kg-1 SC), but not by the mixed 5-HT1 receptor/beta-adrenoceptor antagonist (-)pindolol (2.0 mg kg-1 SC). The failure by (-)pindolol to antagonise the effects of 8-OH-DPAT on raclopride-induced catalepsy could be due to its beta-receptor-blocking properties, since by themselves both (-)pindolol and the selective beta-adrenoceptor antagonist betaxolol (4 mg kg-1 SC) at least partially antagonised the raclopride-induced catalepsy. The present results provide further support for specific interactions between 5-HT1A and DA D2 receptor mechanisms in the mediation of extrapyramidal motor functions in the rat.
给予5-羟色胺1A（5-HT1A）受体激动剂8-羟基-2-（二正丙基氨基）四氢萘（8-OH-DPAT；0.1毫克/千克，皮下注射）可完全对抗多巴胺（DA）D2受体拮抗剂雷氯必利（16毫克/千克，皮下注射）所产生的僵住症。8-OH-DPAT的这一效应又被新型5-HT1A受体拮抗剂（S）-5-氟-8-羟基-2-（二正丙基氨基）四氢萘[（S）-UH-301]（3.5毫克/千克，皮下注射）处理完全对抗，但不被5-HT1受体/β-肾上腺素能受体混合拮抗剂（-）吲哚洛尔（2.0毫克/千克，皮下注射）对抗。（-）吲哚洛尔未能对抗8-OH-DPAT对雷氯必利诱导的僵住症的作用，可能是由于其β受体阻断特性，因为（-）吲哚洛尔和选择性β-肾上腺素能受体拮抗剂倍他洛尔（4毫克/千克，皮下注射）本身至少部分对抗了雷氯必利诱导的僵住症。目前的结果为5-HT1A和DA D2受体机制在介导大鼠锥体外系运动功能中的特异性相互作用提供了进一步的支持。
